Cerebral Medulloepithelioma with Long Survival —Case Report—

Total Page:16

File Type:pdf, Size:1020Kb

Cerebral Medulloepithelioma with Long Survival —Case Report— p428 p.1 [100%] Neurol Med Chir (Tokyo) 47, 428¿433, 2007 Cerebral Medulloepithelioma With Long Survival —Case Report— Masato MATSUMOTO,KazuomiHORIUCHI,TakuSATO, Masahiro OINUMA, Jun SAKUMA,KyouichiSUZUKI,TatsuyaSASAKI,NamioKODAMA, Kazuo WATANABE*, and Toshimitsu SUZUKI* Departments of Neurosurgery and *Pathology, Fukushima Medical University, Fukushima, Fukushima Abstract An 8-year-old boy presented with a rare cerebral medulloepithelioma manifesting as headache, nausea, and vomiting. Neuroimaging demonstrated a mass containing a cyst in the left frontal lobe. Gross total resection of the tumor with a 1-cm margin was performed under intraoperative monitoring. The histological diagnosis was medulloepithelioma. Stereotactic radiotherapy (total dose 20 Gy) was given to the brain up to 1 cm from the surgical margin. Follow-up neuroimaging 5 years later showed no signs of recurrence. He now attends junior high school, with normal mental and physiological development. Medulloepitheliomas are rare, highly malignant embryonal tumors of the central nervous system. Combined gross total tumor resection and radiotherapy are recommended to obtain the most favorable outcome. Key words: medulloepithelioma, cerebrum, prognosis, surgery, radiation Introduction Case Report Medulloepitheliomas, first described by Bailey and An 8-year-old boy was admitted to our hospital Cushing in 1926,2) are rare, highly malignant primi- because of headache, nausea, and vomiting in tive neuroectodermal tumors usually occurring in March 2000. Neurological examination on admis- childhood. Histologically, they resemble the primi- sion showed bilateral papilledema. Routine hemato- tive medullary plate and neural tube.2,28,35) The most logical study disclosed no abnormalities. Computed common site is periventricular within the temporal, tomography (CT) revealed a well-circumscribed parietal, and frontal lobes, in that order.9,11,13,21,22, heterogeneous isodense mass containing a cyst in 44,45,47) These neoplasms are believed to arise from the left frontal lobe, with heterogeneous enhance- primitive undifferentiated matrix cells around the ment with contrast medium (Fig. 1). T1-weighted periventricular area.35) The high rate of recurrence magnetic resonance (MR) imaging showed an isoin- due to rapid subarachnoid spread and radioresis- tense mass, heterogeneously enhanced with gado- tance of the tumor cells results in a poor prognosis linium-diethylenetriaminepenta-acetic acid (Gd- with overall median survival of 5 months.1,3,4,6,9,11, DTPA), containing a cystic component, and hyper- 13,21,22,25,28,32,35,38,43–45,47) Long-term survivors had un- intense areas suggestive of intratumoral hemorrhage dergone gross total resection.25,28,46) (Fig. 2). The preoperative diagnosis was anaplastic We report a case of medulloepithelioma with long- ependymoma. term survival of more than 6 years in a 13-year-old Left frontotemporal craniotomy exposed the boy treated by gross total resection and removal of reddish tumor which was well demarcated from the the surrounding brain tissue infiltrated by tumor adjacent brain (Fig. 3). The tumor was soft and cells. contained a cyst with bloody fluid. The tumor was totally removed after coagulation of the adhering falx. In addition, the surrounding brain was excised to a depth of 1 cm from the margin of the tumor Received October 24, 2006; Accepted June 12, 2007 cavity because intraoperative histological study of 428 p428 p.2 [100%] Cerebral Medulloepithelioma 429 Fig. 1 Computed tomography scans showing a mixed density mass in the left frontal lobe (A), and heterogeneous enhancement of part of the tumor with contrast medium (B). Fig. 4 Photomicrographs of the tumor showing neural tube-like structures with a pseudo- stratified epithelium and internal and exter- nal limiting membrane (A: hematoxylin and eosin [HE] stain, original magnification × 400), mitoses near the internal limiting Fig. 2 T -weighted magnetic resonance images 1 membrane (B: HE stain, original magnifica- showing a well-circumscribed heterogene- tion ×400), rosette formation with the cen- ous mass with hyperintense areas sugges- tral lumen (C) and choroid plexus elements tive of hemorrhage (A), and heterogeneous (D) (C, D: HE stain, original magnification enhancement of the mass by gadolinium (B). ×400), tumor cells infiltrating into the adja- cent parenchyma (E: HE stain, original magnification ×200), and positive immuno- histochemical staining for AE1/AE3 at the luminal border of the neural tube-like struc- tures (F: original magnification ×400). frozen sections showed infiltration by tumor cells. Intraoperative monitoring of motor evoked poten- tial20,41) and somatosensory evoked potential showed no changes during resection of the tumor and sur- rounding brain. Histological examination found various neural tube-like tubular, capillary, and trabecular struc- tures composed of pseudo-stratified primitive neu- Fig. 3 Intraoperative photograph showing a mass roepithelium (Fig. 4A, B). These structures were well demarcated from the surrounding clearly separated from each other by a basement brain. The tumor adhered to the falx membrane positive for periodic acid-Schiff staining. (arrows). The pattern-less cellular areas contained many immature rosette-like structures (Fig. 4C). Vascular proliferation necrosis and calcification were com- Neurol Med Chir (Tokyo) 47, September, 2007 p428 p.3 [100%] 430 M. Matsumoto et al. mon. Foci of choroid plexus-like configurations into glioblasts, i.e. precursors of astrocytes and were also observed (Fig. 4D). Tumor cells had in- oligodendrocytes.14) The glioblasts rapidly migrate filtrated into the surrounding brain tissue (Fig. 4E). outward and retain their mitotic activity. Cells The neural tube-like structures were immunoposi- remaining near the lumen of the neural tube develop tive for cytokeratin (AE1/AE3) (Fig. 4F), and the the features of differentiated ependymal cells. Glial undifferentiated areas were positive for glial fibrilla- cell differentiation occurs during the third stage of ry acidic protein and synaptophysin staining. There cytogenesis.21) Ependymal differentiation is suggest- was no immunoreactivity for epithelial membrane ed by cytokeratin reactivity at the luminal surface, antigen, collagen type IV, alpha-fetoprotein, or indicating the maturation of residual germinative carcinoembryonic antigen. The MIB-1 index for cells located next to the lumen of the original neural proliferative activity was 41.8% for tumor cells in tube, also occurring in the third stage.46) highly cellular portions and 15.5% for those in other The present tumor exhibited some features of overlying areas. ependymal and choroid plexus differentiation. His postoperative course was uneventful and the Moreover, some of the internal and external limiting symptoms attributable to hypertensive intracranial membranes were immunopositive for AE1/AE3. pressure were resolved. He manifested no neurologi- These findings correspond with the third stage of cal deficits. The area up to 1 cm from the surgical cytogenesis. The present tumor was also im- margin was treated with stereotactic radiotherapy munoreactive for vimentin, the first intermediate (total dose 20 Gy). MR imaging obtained 5 years after filament protein demonstrated in the early develop- the operation detected no residual tumor or recur- mental stage of the mammalian neural tube.6,36) rence. At present, the patient attends junior high Medulloepitheliomas may express all stages of cen- school, and his mental and physiological develop- tral neurogenic maturation, from the most em- ment is normal. bryonal to the most differentiated cell types, in a single tumor. It remains unknown why in some Discussion cases the neural tube becomes a malignant tumor and why some individuals develop medulloepithelio- Approximately 50 cases of medulloepithelioma have mas after birth. These tumors may derive from neu- been reported (Table 1).1–19,21–40,42–45) Although most ral tube-like tissue either as a result of neoplastic medulloepitheliomas manifest in the first decade of transformation at some stage of fetal or early life,1,11,13,15,22,25,28,31,39,40,44) they are occasionally found postnatal development11,32,43) or from the anomalous in patients older than 20 years.25,38) These tumors gene re-expression of early neural tube deter- tend to be fatal despite treatment by surgery and/or minants.24,46) irradiation and/or chemotherapy.1,6,10,11,21,22,28,31,38, Medulloepitheliomas at initial presentation gener- 40,44) On the other hand, intraorbital,7,8,15,30) peripher- ally appear as well circumscribed, iso- to slightly al,26) and cauda equina22) medulloepitheliomas have hypodense neoplasms on CT scans,28,31) and as hypo- a much less malignant course and even those treated or hyperintense tumors on T1-andT2-weighted MR primarily or only by enucleation tend not to recur images. Medulloepitheliomas are typically not for a long time.7,15,19,27) Extracranial and intracranial enhanced by contrast medium on CT and MR imag- medulloepitheliomas have similar histological fea- ing,26) but our case showed heterogeneous enhance- tures,8,30) and the great difference in the prognosis ment with iodinated contrast medium and Gd- remains to be elucidated. In addition, the differ- DTPA. This finding may reflect the more aggressive ences in the biological characteristics and behaviors nature of these tumors at recurrence.28) Histological oftheseneoplasmsareunexplained. findings of tumor infiltration into adjacent brain Medulloepithelioma
Recommended publications
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children
    cancer.org | 1.800.227.2345 About Brain and Spinal Cord Tumors in Children Overview and Types If your child has just been diagnosed with brain or spinal cord tumors or you are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children Research and Statistics See the latest estimates for new cases of brain and spinal cord tumors in children in the US and what research is currently being done. ● Key Statistics for Brain and Spinal Cord Tumors in Children ● What’s New in Research for Childhood Brain and Spinal Cord Tumors? What Are Brain and Spinal Cord Tumors in Children? Brain and spinal cord tumors are masses of abnormal cells in the brain or spinal cord 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 that have grown out of control. Are brain and spinal cord tumors cancer? In most other parts of the body, there's an important difference between benign (non- cancerous) tumors and malignant tumors (cancers1). Benign tumors do not invade nearby tissues or spread to distant areas, and are almost never life threatening in other parts of the body. Malignant tumors (cancers) are so dangerous mainly because they can spread throughout the body. Brain tumors rarely spread to other parts of the body, though many of them are considered malignant because they can spread through the brain and spinal cord tissue. But even so-called benign tumors can press on and destroy normal brain tissue as they grow, which can lead to serious or sometimes even life-threatening damage.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • OVERVIEW of POSTER QUICK PITCHES (QP) Short Oral Poster Presentations (Max 3 Min Each) Followed by Discussion Time at the End
    (draft release date 20 May 2021) OVERVIEW OF POSTER QUICK PITCHES (QP) Short oral poster presentations (max 3 min each) followed by discussion time at the end. Time: Daily from 12:00-13:00 hrs | Format: Zoom webinars Monday 31 May: QP 1-4 Tuesday 1 June: QP 5-9 Wednesday 2 June: QP 10-14 Thursday 3 June: QP 15-18 Monday 31 May Quick Pitch 1. Gliomas Chairs: Pieter Wesseling, Signe Regner Michaelsen QP 1.1 P088. Unexpected presentation of an IDH-mutant glioblastoma at Cheryl Coulter autopsy QP 1.2 P089. PAX2 immunoexpression in adult glioblastoma Montserrat Arumí-Uría QP 1.3 P090. The evaluation of palisading necrosis, vascular endothelial Neşe Yeldir proliferation morphology using digital pathology systems and their relations with prognosis QP 1.4 P107. Prognostic role of the proliferation marker Ki-67 in glioblastomas Rikke Hedegaard Dahlrot taking tumor microenvironment, MGMT promoter methylation and post-surgical treatment into account QP 1.5 P109. Stem cell marker ALDH1A3 is not involved in mediating Julian Allgeier radiochemoresistance while RSL-3 induces ferroptotic cell death in C6 glioma model QP 1.6 P110. Differential expression of genes modulating RNA-methylation in Simon Deacon low- and high-grade glioma QP 1.7 P112. The role of aldehyde dehydrogenase 1 (ALDH1) in the treatment of Alicia Gantzkow glioma cells with cold atmospheric plasma (CAP) QP 1.8 P113. Prognostic impact of CDKN2A/B genes deletion and MGMT Maria Fernanda Ruiz promoter gene deletion on diffuse astrocytic tumors QP 1.9 P114. Utility of the new molecular platforms in the study of complex Miguel Idoate pediatric brain tumors QP 1.10 P116.
    [Show full text]
  • WHO Classification of Tumors of the Central Nervous System
    Appendix A: WHO Classification of Tumors of the Central Nervous System WHO Classification 1979 • Ganglioneuroblastoma • Anaplastic [malignant] gangliocytoma and Zülch KJ (1979) Histological typing of tumours ganglioglioma of the central nervous system. 1st ed. World • Neuroblastoma Health Organization, Geneva • Poorly differentiated and embryonal tumours • Glioblastoma Tumours of Neuroepithelial tissue –– Variants: • Astrocytic tumours –– Glioblastoma with sarcomatous compo- • Astrocytoma nent [mixed glioblastoma and sarcoma] –– fibrillary –– Giant cell glioblastoma –– protoplasmic • Medulloblastoma –– gemistocytic –– Variants: • Pilocytic astrocytoma –– desmoplastic medulloblastoma • Subependymal giant cell astrocytoma [ven- –– medullomyoblastoma tricular tumour of tuberous sclerosis] • Medulloepithelioma • Astroblastoma • Primitive polar spongioblastoma • Anaplastic [malignant] astrocytoma • Gliomatosis cerebri • Oligodendroglial tumours • Oligodendroglioma Tumours of nerve sheath cells • Mixed-oligo-astrocytoma • Neurilemmoma [Schwannoma, neurinoma] • Anaplastic [malignant] oligodendroglioma • Anaplastic [malignant] neurilemmoma [schwan- • Ependymal and choroid plexus tumours noma, neurinoma] • Ependymoma • Neurofibroma –– Myxopapillary • Anaplastic [malignant]neurofibroma [neurofi- –– Papillary brosarcoma, neurogenic sarcoma] –– Subependymoma • Anaplastic [malignant] ependymoma Tumours of meningeal and related tissues • Choroid plexus papilloma • Meningioma • Anaplastic [malignant] choroid plexus papil- –– meningotheliomatous [endotheliomatous,
    [Show full text]
  • MP/H Rules Presentation
    Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary Gland, Craniopharyngeal Duct and Pineal Gland 1 Equivalent Terms, Definitions, Charts and Illustrations • Benign and borderline intracranial and CNS tumors have a separate set of rules. 2 Equivalent Terms, Definitions, Charts and Illustrations • PNET (Primitive neuroectodermal tumor) – Central PNET – Supratentorial PNET • pPNET –not brain primary 3 Chart 1 Neuroepithelial Brain CNS • WHO Classification of Tumors of the brain and central nervous system • Not complete listing 4 Chart Instructions: Use this chart to code histology. The tree is arranged Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Embryonal Ependymal Pineal Choroid plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Ependymoma, Pineoblastoma Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) (9390) (9505 Olfactory neurocytoma Oligodendroglioma Ganglioglioma, malignant (9521) anaplastic (9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Atypical Ependymoblastoma Medulloepithelioma Medulloblastoma Supratentorial primitive tetratoid/rhabdoid (9392) (9501) (9470) neuroectodermal tumor tumor (9508) (PNET) (9473) Teratoid Demoplastic (9471)
    [Show full text]
  • Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors
    The American Journal of Pathology, Vol. 188, No. 6, June 2018 ajp.amjpathol.org ANIMAL MODELS Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors Morgan L. Shannon,* Ryann M. Fame,* Kevin F. Chau,*z Neil Dani,* Monica L. Calicchio,* Gwenaelle S. Géléoc,x{ Hart G.W. Lidov,* Sanda Alexandrescu,* and Maria K. Lehtinen*z From the Departments of Pathology* and Otolaryngologyx and the F.M. Kirby Center for Neurobiology,{ Boston Children’s Hospital, Boston; and the Program in Biological and Biomedical Sciences,z Harvard Medical School, Boston, Massachusetts Accepted for publication February 20, 2018. Choroid plexus tumors and ciliary body medulloepithelioma are predominantly pediatric neoplasms. Progress in understanding the pathogenesis of these tumors has been hindered by their rarity and lack Address correspondence to fi Maria K. Lehtinen, Ph.D., of models that faithfully recapitulate the disease. Here, we nd that endogenous Myc proto-oncogene Department of Pathology, Boston protein is down-regulated in the forebrain neuroepithelium, whose neural plate border domains give Children’s Hospital, 300 Long- rise to the anterior choroid plexus and ciliary body. To uncover the consequences of persistent Myc wood Ave., Boston, MA 02115. expression, MYC expression was forced in multipotent neural precursors (nestin-Cre:Myc), which E-mail: maria.lehtinen@ produced fully penetrant models of choroid plexus carcinoma and ciliary body medulloepithelioma. childrens.harvard.edu. Nestin-mediated MYC expression in the epithelial cells of choroid plexus leads to the regionalized formation of choroid plexus carcinoma in the posterior domain of the lateral ventricle choroid plexus and the fourth ventricle choroid plexus that is accompanied by loss of multiple cilia, up-regulation of protein biosynthetic machinery, and hydrocephalus.
    [Show full text]
  • January 2020
    Fred Hutch Cancer Surveillance System January, 2020 REGISTRAR PIP Visit SEER*Educate: A comprehensive training platform for registry professionals Clinical Grade for CNS Primaries Using the WHO Grading System for Selected Tumors of the CNS Mary Trimble, CTR If we have a diagnostic biopsy of a tumor, we can code the clinical grade regardless of the primary site. What is odd about Central Nervous System (CNS) tumors (Figures 1 and 2) is that we can code a clinical grade in the absence of a diagnostic biopsy or histologic confirmation for these primaries. For any other primary, we must have histologic or cytologic confirmation in order to code grade at all. So, what makes the Central Nervous System different? How is it we are able to code clinical grade without any histologic confirmation of the tumor? The World Health Organization (WHO) Classification of Tumors of the Central Nervous System, 4th Edition, released in 2016, provides the WHO grading system of CNS tumors as a uniform way to categorize CNS tumors. Figure 1 Figure 2 Lobes of the Cerebellum Pituitary and Pineal Glands American Joint CommiAee on Cancer (AJCC) Manual, 8th EdiFon - Table 72.2 This four-tiered grade scale helps to classify select CNS histologies based on proliferative potential and the risk of spread or recurrence. In other words, the WHO grade is a malignancy scale where the higher the WHO grade, the more aggressive the clinical course expected for the tumor.” This WHO classification can be seen as part of a larger clinical definition for select histologies and can therefore be used to assign grade without histologic confirmation.
    [Show full text]
  • Primary Cerebral Neuroblastoma: CT and MR Findings in 12 Cases
    115 Primary Cerebral Neuroblastoma: CT and MR Findings in 12 Cases P. C. Davis1 A retrospective CT, MR, and clinical study was performed in 12 patients, five children R. D. Wichman and seven adults, with histologically proved primary CNS neuroblastoma. The CT and Y. Takei MR appearances of this neoplasia were more variable than generally recognized. J. C. Hoffman, Jr. Although seven tumors were predominantly intraparenchymal masses with calcification and cyst formation, five were intra- or juxtaventricular. CT was preferable to noncontrast MR both at initial diagnosis and follow-up for identification of calcification, recurrent tumor at surgical sites, and leptomeningeal disease. Noncontrast MR was useful pri­ marily for localization of peri- and intraventricular lesions. We conclude that primary CNS neuroblastoma has a more variable radiographic appearance than is generally recognized, and that an intra- or periventricular epicenter is common. AJNR 11:115-120, January/February 1990; AJR 154: April1990 Primary cerebral neuroblastoma is a rare neoplasm typically described in children as a large intraparenchymal supratentorial mass frequently containing cysts, calci­ fication , and spontaneous hemorrhage [1-1 0]. This tumor is generally considered to be a specific subset of primitive neuroectodermal tumors, although neuropatho­ logic controversy exists. Detailed electron microscopy may be required for the exact diagnosis. These tumors are malignant lesions with a high rate of recurrence after therapy and frequent subarachnoid metastases. Our experience indicates that primary CNS neuroblastoma has a broader spectrum in presentation, age of onset, location, and radiographic appearance than is generally recognized. We report our experience with primary cerebral neuroblastoma in 12 patients and describe its CT and MR characteristics with clinical, surgical , and histological correlation.
    [Show full text]
  • Molecular Cytogenetic Analysis in the Study of Brain Tumors: Findings and Applications
    Neurosurg Focus 19 (5):E1, 2005 Molecular cytogenetic analysis in the study of brain tumors: findings and applications JANE BAYANI, M.H.SC., AJAY PANDITA, D.V.M., PH.D., AND JEREMY A. SQUIRE, PH.D. Department of Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network; Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children; and Departments of Laboratory Medicine and Pathobiology and Medical Biophysics, University of Toronto, Ontario, Canada Classic cytogenetics has evolved from black and white to technicolor images of chromosomes as a result of advances in fluorescence in situ hybridization (FISH) techniques, and is now called molecular cytogenetics. Improvements in the quality and diversity of probes suitable for FISH, coupled with advances in computerized image analysis, now permit the genome or tissue of interest to be analyzed in detail on a glass slide. It is evident that the growing list of options for cytogenetic analysis has improved the understanding of chromosomal changes in disease initiation, progression, and response to treatment. The contributions of classic and molecular cytogenetics to the study of brain tumors have pro- vided scientists and clinicians alike with new avenues for investigation. In this review the authors summarize the con- tributions of molecular cytogenetics to the study of brain tumors, encompassing the findings of classic cytogenetics, interphase- and metaphase-based FISH studies, spectral karyotyping, and metaphase- and array-based comparative genomic hybridization. In addition, this review also details the role of molecular cytogenetic techniques in other aspects of understanding the pathogenesis of brain tumors, including xenograft, cancer stem cell, and telomere length studies.
    [Show full text]